Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
463.86
-5.82 (-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
69
70
Next >
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
↗
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
3 Secret Stocks to Double Your Money by 2028
↗
February 22, 2024
Vertex Pharmaceuticals (VRTX), UiPath (PATH), and Science Applications International (SAIC) are 3 secret stocks to double your money by 2028.
Via
InvestorPlace
Vertex to Participate in Upcoming Investor Conferences
February 20, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
What Analysts Are Saying About Vertex Pharmaceuticals Stock
↗
February 20, 2024
Via
Benzinga
Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market
↗
February 20, 2024
Vertex's main business may be heading for a new era of growth...
Via
The Motley Fool
Stock-Split Watch: Is Vertex Pharmaceuticals Next?
↗
February 14, 2024
It's on track to launch more blockbuster drugs.
Via
The Motley Fool
Could Vertex Pharmaceuticals Reach $500 in 2024?
↗
February 10, 2024
Vertex shares have several catalysts on the horizon...
Via
The Motley Fool
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
↗
February 08, 2024
Its pain medicine isn't precisely what it hoped for, but it could still sell.
Via
The Motley Fool
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
↗
February 20, 2024
These exciting players could deliver explosive growth over time.
Via
The Motley Fool
3 Revolutionary Biotech Stocks Poised for 10X Surge
↗
February 19, 2024
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.
Via
InvestorPlace
3 Magnificent Growth Stocks to Buy Right Now
↗
February 19, 2024
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.
Via
The Motley Fool
Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?
↗
February 18, 2024
The pain market is in great need of new options.
Via
The Motley Fool
2 Top Growth Stocks to Buy With $1,000 Right Now
↗
February 18, 2024
Even a modest starting investment in the right stocks could pay off in the years ahead.
Via
The Motley Fool
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
↗
February 17, 2024
Sometimes, the winning move doesn't look right at first.
Via
The Motley Fool
2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now
↗
February 17, 2024
The healthcare industry often remains resilient amid macro headwinds, and these two stocks are prime examples.
Via
The Motley Fool
Giving Uber Its Due
↗
February 15, 2024
We've also got a look at good news from Chipotle and Roblox, and we put some stocks on a dating show.
Via
The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.
↗
February 15, 2024
These stocks have what it takes to drive superior returns in the years to come.
Via
The Motley Fool
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
↗
February 15, 2024
There's more to consider with Vertex's valuation than one number.
Via
The Motley Fool
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
↗
February 13, 2024
You can't go back in the past, but it's not too late to invest in this top stock.
Via
The Motley Fool
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
February 13, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 Healthcare Stocks That Could Help Set You Up for Life
↗
February 12, 2024
These rock-solid businesses can add meaningful returns to a long-term portfolio.
Via
The Motley Fool
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
↗
February 11, 2024
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.
Via
InvestorPlace
Is Vertex Pharmaceuticals Stock a Buy Now?
↗
February 10, 2024
The company just released its latest earnings report, and growth investors may be a little disappointed.
Via
The Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
↗
February 10, 2024
These businesses are built to last.
Via
The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
↗
February 10, 2024
Companies in the healthcare industry tend to generate returns in a wide range of market environments.
Via
The Motley Fool
3 Stocks That Could Trounce the Market in 2024
↗
February 10, 2024
These stocks appear to have what it takes to beat the market this year.
Via
The Motley Fool
3 Growth Stocks With More Potential Than Any Cryptocurrency
↗
February 09, 2024
The stock market is full of opportunities for investors of all risk appetites and trading styles.
Via
The Motley Fool
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
↗
February 09, 2024
These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.
Via
InvestorPlace
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
↗
February 08, 2024
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
69
70
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.